Randomized trial evaluates protective immunity from an intranasal adenoviral influenza vaccine, suggesting efficacy for broader protection.
Frequent antigenic drift in influenza viruses necessitates broadly protective vaccines. This study evaluated an intranasal adenoviral-vector vaccine expressing influenza A nucleoprotein (NP) fused to the autophagy-inducing peptide C5. A heterologous prime-boost regimen using chimpanzee and bovine adenoviral platforms induced strong NP-specific humoral and cellular immune responses in mice. High serum and lung IgG/IgA level were detected, accompanied by enhanced antibody-dependent cellular cytotoxicity. Cellular analyses revealed potent NP-specific cytokine responses and expansion of effector memory (T EM ) and tissue-resident memory (T RM ) T cells, particularly CD8 + T RM , in the lungs. Experiments using immune-deficient mice showed that B cells and CD8 + T cells independently contributed to early viral clearance. Adoptive transfer studies demonstrated that lung-derived T cells conferred the strongest heterosubtypic viral restriction, whereas systemic T cells and antibodies provided partial protection. Together, these findings highlight the critical role of lung-resident T cells in cross-protective viral control, supporting intranasal NP-based adenoviral vaccines as promising universal influenza vaccine candidates.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: